Sanofi Contingent Value Rights
GCVRZ
GCVRZ was delisted on the 3rd of March, 2020.
118 hedge funds and large institutions have $91.5M invested in Sanofi Contingent Value Rights in 2014 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 13 increasing their positions, 34 reducing their positions, and 14 closing their positions.
53% more capital invested
Capital invested by funds: $59.7M → $91.5M (+$31.8M)
7% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 14
0% more funds holding
Funds holding: 118 → 118 (0)
62% less repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 34
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$2.4M |
| 2 |
LCM
Lonestar Capital Management
San Francisco,
California
|
+$888K |
| 3 |
CPM
Chesapeake Partners Management
Baltimore,
Maryland
|
+$332K |
| 4 |
SAM
Silverback Asset Management
Chapel Hill,
North Carolina
|
+$69.5K |
| 5 |
CCA
Catalyst Capital Advisors
Huntington,
New York
|
+$46.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCM
Gruss Capital Management
New York
|
-$3.02M |
| 2 |
NM
Newtyn Management
New York
|
-$822K |
| 3 |
BPGAM
BTG Pactual Global Asset Management
Hamilton,
Bermuda
|
-$372K |
| 4 |
MCM
Mason Capital Management
New York
|
-$278K |
| 5 |
WA
Whitebox Advisors
Minneapolis,
Minnesota
|
-$250K |
GCVRZ Hedge Fund Activity: Q4 2014 in Review
118 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Sanofi Contingent Value Rights (GCVRZ) for Q4 2014, worth a combined $91.5M — up 53% from $59.7M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new GCVRZ positions and 14 closed out — a net gain of 1 holder — while 13 added to existing stakes and 34 trimmed.
The largest buyer was Oxford Asset Management, opening a new position worth an estimated $2.4M. The largest seller was Gruss Capital Management, cutting an estimated $3.02M.
- 118 institutional investors held Sanofi Contingent Value Rights (GCVRZ) as of Q4 2014, unchanged from Q3 2014.
- Funds reported $91.5M of Sanofi Contingent Value Rights stock for Q4 2014, up 53% quarter-over-quarter.
- 15 funds opened new Sanofi Contingent Value Rights positions in Q4 2014 and 14 closed out, a net change of +1 holder.
- The largest Sanofi Contingent Value Rights buyer in Q4 2014 was Oxford Asset Management, an estimated $2.4M added.
- The largest Sanofi Contingent Value Rights seller in Q4 2014 was Gruss Capital Management, an estimated $3.02M sold.
Based on aggregated 13F filings for Q4 2014.